融资丨陕西天宠获Pre-A轮数千万级融资

Financing Event - On June 10, Shaanxi Tiancare announced the completion of a Pre-A round financing of several tens of millions, exclusively invested by Xi'an Urban Agriculture Investment Co., Ltd [3] - The financing will focus on the research and development of innovative pet pharmaceuticals, the industrialization of biological agents, and the construction of an internationally leading GMP production base [3] Company Overview - Shaanxi Tiancare Biotechnology Co., Ltd was established in 2016, specializing in the research, production, and sales of innovative pet drugs and high-end pet medical products [5] - The company has established a municipal-level pet drug engineering research and development center and an experimental animal base, forming an innovative pattern of "two schools and one enterprise" [5] - The research pipeline covers six major areas: parasitology, oncology, endocrinology, anti-infection, and anti-inflammatory analgesia [5] Collaborations - Shaanxi Tiancare has established a "Pet Drug Creation Joint Laboratory" in collaboration with China Pharmaceutical University, focusing on the development of new sustained-release chemical drug formulations [7] - The company is also collaborating deeply with Northwest A&F University to make breakthroughs in key technologies for recombinant protein drugs in the field of biological agents [7] - The first cat subunit vaccine biological agent has completed preclinical research and is expected to be launched in 2027 [7] Investor Overview - Xi'an Urban Agriculture Investment Co., Ltd was established in September 2023 with a registered capital of 1 billion RMB, serving as a wholly-owned subsidiary of Xi'an Agricultural Investment Group [9] - The company focuses on capital operation, industrial investment, and financial services, aiming to build a 3+1+X urban agricultural investment system centered on "industrial investment + park incubation + supply chain finance" [9]